Advertisement


Milan Radovich, PhD, on ctDNA After Neoadjuvant Chemotherapy and Recurrence in Triple-Negative Breast Cancer

2019 San Antonio Breast Cancer Symposium

Advertisement

Milan Radovich, PhD, of Indiana University School of Medicine, discusses trial findings that show patients with triple-negative breast cancer who are at high risk of relapse after receiving preoperative chemotherapy can be risk-stratified based on the presence of minimal residual disease as determined by circulating tumor DNA and circulating tumor cells (Abstract GS5-02).



Related Videos

Breast Cancer

Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer

Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast cancer in women who discontinued endocrine therapy at 5 years is likely to be about a third lower now than in his group’s previous report (Abstract GS2-04).

Breast Cancer
Immunotherapy

Luca Gianni, MD, on the Neoadjuvant Treatment of Triple-Negative Breast Cancer

Luca Gianni, MD, of the Fondazione Michelangelo, discusses findings from the NeoTRIP trial on pathologic complete response to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk, and locally advanced breast cancer (Abstract GS3-04).

Breast Cancer

Joerg Heil, MD, PhD, on Image-Guided Vacuum-Assisted Breast Biopsy

Joerg Heil, MD, PhD, of the University Hospital Heidelberg, discusses findings on how accurately this technique can diagnose residual disease and pathologic complete response after neoadjuvant chemotherapy in patients with breast cancer. These data may help tailor, de-escalate, and potentially avoid unnecessary surgeries (Abstract GS5-03).

Breast Cancer
Immunotherapy

Ariella B. Hanker, PhD, on Therapeutic Implications of HER2 and HER3 Mutations in Breast Cancer

Ariella B. Hanker, PhD, of UT Southwestern Medical Center, discusses data showing that breast cancers expressing co-occurring HER2 and HER3 mutations may require the addition of a phosphoinositide 3-kinase alpha inhibitor to a HER2 tyrosine kinase inhibitor (Abstract GS6-04).

Breast Cancer

Joseph Sparano, MD: The William L. McGuire Memorial Lecture

Joseph Sparano, MD, of the Montefiore Medical Center, discusses three challenges:

  • How can gene-expression profiles and other diagnostic tests be used to guide the use of adjuvant systemic therapy?
  • Is it time to reappraise active surveillance?
  • Are there diagnostic and therapeutic strategies that can identify tumors at highest risk of metastasis, and novel therapies that can block the spread of disease?

Advertisement

Advertisement



Advertisement